share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  07/04 04:16
牛牛AI助理已提取核心訊息
On July 3, 2024, Apollomics Inc., a late-stage clinical biopharmaceutical company, announced a strategic shift to focus on the clinical development of vebreltinib for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations. This decision is aimed at addressing a significant unmet medical need. The company's SPARTA Phase 2 clinical trial will continue enrolling NSCLC patients with Met amplification and follow current patients with solid tumors with MET alterations. Leadership changes were also announced, with co-founder and President Sanjeev Redkar, Ph.D., and Chief Medical Officer Peony Yu, M.D., transitioning to consulting roles in August. These changes are part of a cost reduction plan that is expected to reduce ongoing operating expenses by over 50% and extend the company's capital runway into the third quarter of 2025. Vebreltinib, a c-MET inhibitor, has shown promise in preclinical models and has received conditional approval from China's NMPA, though it is not yet approved elsewhere.
On July 3, 2024, Apollomics Inc., a late-stage clinical biopharmaceutical company, announced a strategic shift to focus on the clinical development of vebreltinib for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations. This decision is aimed at addressing a significant unmet medical need. The company's SPARTA Phase 2 clinical trial will continue enrolling NSCLC patients with Met amplification and follow current patients with solid tumors with MET alterations. Leadership changes were also announced, with co-founder and President Sanjeev Redkar, Ph.D., and Chief Medical Officer Peony Yu, M.D., transitioning to consulting roles in August. These changes are part of a cost reduction plan that is expected to reduce ongoing operating expenses by over 50% and extend the company's capital runway into the third quarter of 2025. Vebreltinib, a c-MET inhibitor, has shown promise in preclinical models and has received conditional approval from China's NMPA, though it is not yet approved elsewhere.
2024年7月3日，臨床後期生物製藥公司阿波羅米克斯公司宣佈戰略轉型，專注於發展針對非小細胞肺癌（NSCLC）患者MET突變的vebreltinib的臨床研究，旨在解決重大、尚未得到滿足的醫療需求。該公司的SPARTA第2期臨床試驗將繼續招募MET擴增的NSCLC患者，並隨訪當前的固腫瘤患者。同時宣佈了領導層變動，其中聯合創始人兼總裁Sanjeev Redkar博士和首席醫學官Peony Yu博士將於8月份轉任諮詢角色。這些變化是成本削減計劃的一部分，預計將減少營業費用超過50％，並將公司的資本儲備延長至2025年第三季度。vebreltinib是一種c-MET抑制劑，在臨床前模型中表現出良好的前景，並已獲得中國國家藥品監督管理局的條件批准，但在其他地區尚未獲得批准。
2024年7月3日，臨床後期生物製藥公司阿波羅米克斯公司宣佈戰略轉型，專注於發展針對非小細胞肺癌（NSCLC）患者MET突變的vebreltinib的臨床研究，旨在解決重大、尚未得到滿足的醫療需求。該公司的SPARTA第2期臨床試驗將繼續招募MET擴增的NSCLC患者，並隨訪當前的固腫瘤患者。同時宣佈了領導層變動，其中聯合創始人兼總裁Sanjeev Redkar博士和首席醫學官Peony Yu博士將於8月份轉任諮詢角色。這些變化是成本削減計劃的一部分，預計將減少營業費用超過50％，並將公司的資本儲備延長至2025年第三季度。vebreltinib是一種c-MET抑制劑，在臨床前模型中表現出良好的前景，並已獲得中國國家藥品監督管理局的條件批准，但在其他地區尚未獲得批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。